Related Experiment Video

Updated: Sep 21, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

[Antithrombin III, protein C and protein S in children with chronic viral hepatitis B or C]

Inga Adamska1, Anna Szaflarska-Szczepanik, Andrzej Chrobot

  • 1Katedra i Klinika Pediatrii, Alergologii i Gastroenterologii, Akademia Medyczna, ul. M. Skłodowskiej-Curie 9, 85-094 Bydgoszcz, Poland.

Medycyna Wieku Rozwojowego
|July 25, 2003
PubMed

Insights

In children with chronic viral hepatitis B or C, blood coagulation factors antithrombin III, protein C, and protein S showed no significant correlation with disease severity or fibrosis. These findings suggest coagulation abnormalities are not directly linked to hepatitis activity in pediatric patients.

Area of Science:

  • Hepatology
  • Hematology
  • Pediatric Infectious Diseases

Context:

  • Viral hepatitis, particularly chronic hepatitis B and C, can impact various physiological systems.
  • Coagulation abnormalities are recognized complications in liver disease.
  • Pediatric chronic viral hepatitis requires understanding its systemic effects.

Purpose:

  • To investigate the levels of key coagulation proteins (antithrombin III, protein C, protein S) in children with chronic viral hepatitis B or C.
  • To determine if these coagulation parameters correlate with the degree of hepatic histological activity and fibrosis.
  • To compare coagulation profiles in pediatric patients with chronic viral hepatitis against a control group.

Summary:

  • This study measured antithrombin III, protein C, and protein S levels in 100 children (ages 3-17) diagnosed with chronic hepatitis B or C.
  • No statistically significant correlation was found between these coagulation parameters and the histological activity or fibrosis stage in the affected children.
  • Furthermore, no significant differences were observed when comparing coagulation parameters between the patient group and a control group.

Impact:

  • These findings indicate that routine assessment of antithrombin III, protein C, and protein S may not be necessary for monitoring disease activity or fibrosis in pediatric chronic viral hepatitis.
  • Highlights the need for further research into the specific mechanisms of coagulation disturbances in pediatric liver diseases.
  • Provides baseline data for future studies on thrombotic or hemorrhagic risks in children with chronic viral hepatitis.

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.